What is the optimal treatment approach for a 70-year-old patient with intestinal-type adenocarcinoma of the gastric antrum presenting with gastric outlet obstruction?

Treatment Approach for 70-Year-Old with Intestinal-Type Adenocarcinoma of the Antrum with Gastric Outlet Obstruction

For a 70-year-old with gastric antral adenocarcinoma and outlet obstruction, immediate relief of obstruction via endoscopic stenting is the priority, followed by staging to determine if the patient is a candidate for curative-intent gastrectomy (with or without neoadjuvant chemotherapy) versus palliative systemic therapy. 1

Initial Management: Relieve the Obstruction

The first step is addressing the gastric outlet obstruction to restore oral intake and improve quality of life:

Endoscopic Stenting (First-Line for Immediate Relief)

• Placement of enteral stent provides rapid symptom relief (typically within 24-48 hours) with minimal invasiveness 1
• This is preferred for acute management and allows time for proper staging and treatment planning
• Faster improvement in oral intake and shorter hospitalization compared to surgery 2
• Common pitfall: Stents have higher re-obstruction rates (up to 18-40%), so this may be better suited for patients with limited life expectancy or as a bridge to definitive therapy 3, 4

Alternative Decompression Options

If endoscopic stenting is not feasible or fails:

• Venting gastrostomy for gastric decompression when endoscopic intervention is unsuccessful 1
• Drain any ascites before gastrostomy placement to reduce infectious complications 1
• Nasogastric tube only for acute management—avoid prolonged use 5

Staging and Treatment Intent Determination

After relieving obstruction, determine if curative-intent treatment is possible:

For Potentially Resectable Disease (Localized/Regional)

Gastrectomy in select patients is recommended even with outlet obstruction 1:

• Recent evidence shows gastric outlet obstruction should NOT be an absolute contraindication to neoadjuvant chemotherapy when adequate nutritional support is provided 6
• Patients receiving neoadjuvant therapy completed planned treatment in most cases, with comparable R0 resection rates to upfront surgery 6
• However, no survival benefit was demonstrated for neoadjuvant therapy versus upfront surgery in this population (median OS ~19 months for both approaches) 6

Decision algorithm for curative-intent treatment:

• Age <75 years, good performance status (ECOG 0-1), no distant metastases: Consider upfront gastrectomy or neoadjuvant chemotherapy followed by gastrectomy
• Neoadjuvant chemotherapy option: Fluoropyrimidine + oxaliplatin (preferred over cisplatin for lower toxicity) for 2-3 cycles, then reassess for resection 7, 1
• Upfront surgery may be preferred given lack of survival benefit from neoadjuvant therapy and to avoid nutritional deterioration during chemotherapy 6

For Unresectable/Metastatic Disease (Palliative Intent)

Performance status determines treatment approach 1:

Good Performance Status (ECOG 0-2, KPS ≥60%)

Offer systemic therapy plus best supportive care:

First-line systemic therapy 7, 1:

• Test for HER2, PD-L1 (CPS), and MSI/dMMR status before initiating therapy
• HER2-positive: Trastuzumab + fluoropyrimidine + platinum (cisplatin category 1, oxaliplatin category 2A) 1
  • Pembrolizumab can be added to this regimen 1
• HER2-negative with PD-L1 CPS ≥5: Nivolumab + fluoropyrimidine + oxaliplatin (category 1) 1
• HER2-negative with PD-L1 CPS <5: Fluoropyrimidine + oxaliplatin (preferred) or cisplatin 7, 1
• Doublet regimens preferred over triplets due to lower toxicity, especially in a 70-year-old 7, 1

Surgical gastrojejunostomy considerations for palliative patients:

• Provides more durable palliation than stenting, especially if expected survival >6 months 3, 4, 2
• Palliative resection showed survival benefit in retrospective data (median survival longest in resection group) 2
• Consider in medically fit patients with good performance status and localized disease burden 1

Poor Performance Status (ECOG ≥3, KPS <60%)

Offer palliative/best supportive care only 1:

• Pharmacological symptom management: opioids, antiemetics, antisecretory agents 5
• Nutritional support via feeding jejunostomy tube for distal obstruction 1
• Chemotherapy provides survival benefit (8 vs 5 months) but only in patients with adequate performance status 1

Nutritional Support

Early nutritional assessment is essential 5:

• Feeding jejunostomy tube for patients with mid/distal gastric obstruction who cannot maintain oral intake 1
• Place feeding tubes if tumor location permits and oral diet cannot be resumed after obstruction relief
• Critical for maintaining performance status during systemic therapy

Key Clinical Pitfalls

1. Don't delay staging: Endoscopic stenting buys time but complete staging (CT chest/abdomen/pelvis, HER2/PD-L1/MSI testing) must proceed urgently to determine curative versus palliative intent
2. Don't assume obstruction precludes curative treatment: Recent data shows neoadjuvant chemotherapy is feasible with proper support, though upfront surgery may be preferred 6
3. Don't use stenting alone for long-term palliation: If survival expected >6 months, surgical gastrojejunostomy provides more durable relief 3, 4, 2
4. Don't offer chemotherapy to poor performance status patients: ECOG ≥3 or KPS <60% should receive supportive care only 1